Read
- Veteran bands Motorhead, Black Sabbath top Metal Hammer Golden Gods
- Analysis - French EU-wariness complicates life for Hollande
- Golfing in Iceland's midnight sun - lava beds, angry birds, winds
- Vodafone may trump Liberty with $10 billion cash bid for Kabel - sources
- BoE, still divided, flags market impact of Fed uncertainty
Pfizer kidney cancer drug fails as initial treatment
The entrance of Pfizer World headquaters in New York City, August 31, 2003.
Credit: Reuters/Jeff Christensen
(Reuters) - Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.
The trial was testing the drug Inlyta in patients who have received no prior treatments and compared its effects with another kidney cancer drug, sorafenib. Inlyta is already approved to treat kidney cancer that has not responded to prior therapy.
Sorafenib is marketed as Nexavar by Onyx Pharmaceuticals Inc and Germany's Bayer AG. (Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters